We frequently receive regulatory questions about the increasing number and variety of healthcare apps being developed in Japan and elsewhere in the world. From a regulatory point of view, the most important issue is whether a particular app will be treated as a regulated medical device under the Pharmaceutical and Medical Devices Act (PMD Act). In the first installment of our "Japan Medical Devices Law Podcast" series, Ryosuke Tateishi, our regulatory and compliance partner, Mami Ohara, an industry specialist with experience in corporate transactions, and Fei Zhou, our finance and investment specialist, take a closer look at recent developments and introduce the regulatory landscape surrounding healthcare apps in Japan.
Podden och tillhörande omslagsbild på den här sidan tillhör
Baker McKenzie. Innehållet i podden är skapat av Baker McKenzie och inte av,
eller tillsammans med, Poddtoppen.
